International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2025
Evaluation of Mycoplasma genitalium positivity and co-infection with Chlamydia trachomatis and/or Neisseria gonorrhoeae at various care sites across the United States.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lillis Rebecca, Arcenas Rodney, Boraas Christy M, Chavoustie Steven E, Crane LaShonda, d'Empaire Nicole, Ermel Aaron C, Harnett Glenn, Hinestrosa Federico, House Stacey, Miller Joseph, Mills Anthony, Poblete Ronald, Young Stephen, Van Der Pol Barbara, Liat CT/NG/MG Clinical Trial Study Group
Аннотация
OBJECTIVES: We evaluated Mycoplasma genitalium (MG) positivity and co-infection with Chlamydia trachomatis (CT) and/or Neisseria gonorrhoeae (NG), based on results from a trial assessing clinical performance of the Cobas® Liat CT/NG/MG point-of-care test.
METHODS: A prospective, US, multicenter, noninterventional study assessed MG positivity in prospective urine samples (male) and clinician-collected vaginal swabs (female) from symptomatic/asymptomatic patients aged ≥14 years attending various clinical settings. Participants were designated positive or negative for MG, CT, and NG based on combined results from three US Food and Drug Administration-approved assays and one laboratory-developed test. MG co-infection with CT and/or NG was assessed.
RESULTS: Among 4818 evaluable participants, median age was 35.0 years (range: 15.0-81.0), 40.3% were symptomatic, and 51.6% were assigned female sex at birth. MG positivity was 9.6% overall (symptomatic participants: 11.6%; asymptomatic participants: 8.2%). Among 4811 participants with valid results for all analytes, 0.1% were positive for MG, CT, and NG, 1.0% were co-infected with MG/CT; and 0.3% were co-infected with MG/NG.
CONCLUSIONS: MG positivity was high and MG co-infection with CT was common. These findings improve understanding of MG prevalence and may help inform the targeting of MG screening to specific patient populations. Co-infection data support using multiplex testing to facilitate targeted treatment decisions.
METHODS: A prospective, US, multicenter, noninterventional study assessed MG positivity in prospective urine samples (male) and clinician-collected vaginal swabs (female) from symptomatic/asymptomatic patients aged ≥14 years attending various clinical settings. Participants were designated positive or negative for MG, CT, and NG based on combined results from three US Food and Drug Administration-approved assays and one laboratory-developed test. MG co-infection with CT and/or NG was assessed.
RESULTS: Among 4818 evaluable participants, median age was 35.0 years (range: 15.0-81.0), 40.3% were symptomatic, and 51.6% were assigned female sex at birth. MG positivity was 9.6% overall (symptomatic participants: 11.6%; asymptomatic participants: 8.2%). Among 4811 participants with valid results for all analytes, 0.1% were positive for MG, CT, and NG, 1.0% were co-infected with MG/CT; and 0.3% were co-infected with MG/NG.
CONCLUSIONS: MG positivity was high and MG co-infection with CT was common. These findings improve understanding of MG prevalence and may help inform the targeting of MG screening to specific patient populations. Co-infection data support using multiplex testing to facilitate targeted treatment decisions.